This research is a prospective study in which the purpose is to investigate the clinical outcomes following the transfer of a mosaic embryo (presence of both chromosomally normal and abnormal cells) that has been screened for preimplantation genetic testing (PGT).
This research is a prospective study with the purpose is to investigate the clinical outcomes following the transfer of a mosaic embryo (presence of both chromosomally normal and abnormal cells) that has been screened for preimplantation genetic testing (PGT). PGT involves the biopsy and testing of a handful (3-6) of trophectoderm (pre-placental cells) from the embryo. Embryos that are screened as mosaic via PGT, as a standard, are not offered for transfer for pregnancy attempt. Publications have shown that mosaic embryos and mosaic fetuses can result in healthy live births (Wallerstein et al, 2015; Victor et al, 2019). Ongoing clinical outcomes are important to further understand the association between an embryonic mosaic biopsy of pre-placental cells and subsequent fetal chromosomal constitution. Implantation rates and live birth rates will be evaluated to help understand if mosaic embryos should routinely be offered for transfer to patients attempting pregnancy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
250
Subjects will transfer a mosaic embryo transferred to their uterus
Colorado Center for Reproductive Medicine
Lone Tree, Colorado, United States
RECRUITINGEvaluation of Implantation rate
Ultrasound will be performed 2-3 weeks after initial positive pregnancy test to confirm viable pregnancy as evidenced by gestational sac in the uterus with a fetal heat rate
Time frame: 3-4 weeks after embryo transfer
Live birth rate
Live birth rate will be evaluated
Time frame: 9-12 months post embryo transfer
Miscarriage Rates
The rate of miscarriage will be evaluated associated with a mosaic embryo transfer
Time frame: 5-12 months post embryo transfer
Products of conception from miscarriage
Products of conception will be karyotyped if available following a miscarriage and compared to that of previous PGT testing if the patient is willing to have the testing.
Time frame: 2-9 months post embryo transfer
Pregnancy complications
Patient will be evaluated after delivery to assess if patient had any complications associated with the pregnancy. This will be completed with telephone interview
Time frame: 9-12 months post embryo transfer
Stillbirth rates associated with Mosaic Embryo Transfer
The rate of stillbirths with will be evaluated among patients who have had a mosaic embryo transfer
Time frame: 9-12 months post embryo transfer
Prenatal testing
If available, we will request any results of prenatal testing of karyotype that was obtained via Amniocentesis or Chorionic Villa Sampling (CVS)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 9-12 months post embryo transfer
Neonatal Outcomes
Patient will be contacted to assess the health of the infant, noting any medical problems if any that the baby has.
Time frame: 12-15 months after birth of baby